Gyre Therapeutics (NASDAQ:GYRE – Get Free Report) and Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, earnings, dividends, valuation, risk and institutional ownership.
Analyst Recommendations
This is a breakdown of recent ratings and target prices for Gyre Therapeutics and Axsome Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Gyre Therapeutics | 2 | 0 | 1 | 0 | 1.67 |
| Axsome Therapeutics | 1 | 2 | 17 | 1 | 2.86 |
Gyre Therapeutics presently has a consensus target price of $16.00, suggesting a potential upside of 125.99%. Axsome Therapeutics has a consensus target price of $275.84, suggesting a potential upside of 58.22%. Given Gyre Therapeutics’ higher probable upside, research analysts clearly believe Gyre Therapeutics is more favorable than Axsome Therapeutics.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| Gyre Therapeutics | -15.47% | -6.57% | -5.35% |
| Axsome Therapeutics | -24.68% | -265.55% | -28.10% |
Risk & Volatility
Gyre Therapeutics has a beta of 1.89, indicating that its share price is 89% more volatile than the S&P 500. Comparatively, Axsome Therapeutics has a beta of 0.86, indicating that its share price is 14% less volatile than the S&P 500.
Valuation and Earnings
This table compares Gyre Therapeutics and Axsome Therapeutics”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Gyre Therapeutics | $116.59 million | 6.77 | $5.03 million | ($0.21) | -33.71 |
| Axsome Therapeutics | $638.50 million | 14.30 | -$183.17 million | ($3.75) | -46.49 |
Gyre Therapeutics has higher earnings, but lower revenue than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Gyre Therapeutics, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
24.0% of Gyre Therapeutics shares are held by institutional investors. Comparatively, 81.5% of Axsome Therapeutics shares are held by institutional investors. 9.5% of Gyre Therapeutics shares are held by insiders. Comparatively, 20.6% of Axsome Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Summary
Gyre Therapeutics beats Axsome Therapeutics on 8 of the 15 factors compared between the two stocks.
About Gyre Therapeutics
Gyre Therapeutics, Inc., a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases. In addition, it advances a product pipeline in China, including Pirfenidone, for dermatomyositis interstitial lung disease, systemic sclerosis-associated interstitial lung disease, and pneumoconiosis, as well as for diabetic kidney disease; and product candidates for acute-on-chronic liver failure, chronic obstructive pulmonary disease, and pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California.
About Axsome Therapeutics
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer’s disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.
Receive News & Ratings for Gyre Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gyre Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
